Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques

• Rebecca Broeckel ,

  Contributed equally to this work with: Rebecca Broeckel, Julie M. Fox, Nicole Haese

  Affiliation Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America

  ⨯
• Julie M. Fox ,

  Contributed equally to this work with: Rebecca Broeckel, Julie M. Fox, Nicole Haese

  Affiliation Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, United States of America

  ⨯
• Nicole Haese ,

  Contributed equally to this work with: Rebecca Broeckel, Julie M. Fox, Nicole Haese

  Affiliation Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America

  ⨯
• Craig N. Kreklywich,

  Affiliation Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America

  ⨯
• Soila Sukulpovi-Petty,

  Affiliation Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, United States of America

  ⨯
• Alfred Legasse,

  Affiliation Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, United States of America

  ⨯
• Patricia P. Smith,

  Affiliation Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America

  ⨯
• Michael Denton,

  Affiliation Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America

  ⨯
• Carsten Corvey,

  Affiliation Sanofi, Cambridge, United States of America

  ⨯
• Shiv Krishnan,

  Affiliation Sanofi, Cambridge, United States of America

  ⨯
• Lois M. A. Colgin,

  Affiliation Pathology Services Unit, Division of Comparative Medicine, Oregon National Primate Research Center, Beaverton, United States of America

  ⨯
• Rebecca M. Ducore,

  Affiliation Pathology Services Unit, Division of Comparative Medicine, Oregon National Primate Research Center, Beaverton, United States of America

  ⨯
• Anne D. Lewis,

  Affiliation Pathology Services Unit, Division of Comparative Medicine, Oregon National Primate Research Center, Beaverton, United States of America

  ⨯
• Michael K. Axthelm,

  Affiliations Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America, Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, United States of America

  ⨯
• Marie Mandron,

  Affiliation Sanofi, Marcy L’Etoile, France

  ⨯
• Pierre Cortez,

  Affiliation Sanofi, Marcy L’Etoile, France

  ⨯
• Jonathan Rothblatt,

  Affiliation Sanofi, Cambridge, United States of America

  ⨯
• Ercole Rao,

  Affiliation Sanofi, Marcy L’Etoile, France

  ⨯
• Ingo Focken,

  Affiliation Sanofi, Marcy L’Etoile, France

  ⨯
• Kara Carter,

  Affiliation Sanofi, Cambridge, United States of America

  ⨯
• Gopal Sapparapau,

  Affiliation Departments of Pediatrics and Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, United States of America

  ⨯
• James E. Crowe Jr.,

  Affiliation Departments of Pediatrics and Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, United States of America

  ⨯
• Michael S. Diamond,

  Affiliation Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, United States of America

  ⨯
•  [ ... ],
• Daniel N. Streblow

  * E-mail: streblow@ohsu.edu

  Affiliations Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America, Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, United States of America

  http://orcid.org/0000-0002-6828-2492

  ⨯
• [ view all ]
• [ view less ]